EUKON Legality Rating awarded
Caserta, ITALY – 03 Feb 2026 Legality Rating awarded 🚀…
Gender matter! EUKON move on mission 5
Caserta, ITALY – August 8th, 2023 We are absolutely…
IVUS + NIRS: The PROSPECT II Study
The PROSPECT II study was presented as Late-Breaking Clinical Trials during TCT Connect 2020
Click The PROSPECT II Study for presentation
Latest News:
EUKON FT1000 ranking 2022 on Financial Times
FT 1000: the sixth annual list of Europe’s fastest-growing companies…